Genetic rescue of glycosylation-deficient FGF23 in the GALNT3 knockout mouse

Endocrinology (United States)

Volumn 155, Issue 10, 2014, Pages 3891-3898

  Ichikawa, Shoji ^a   Gray, Amie K ^a   Padgett, Leah R ^a   Allen, Matthew R ^a   Clinkenbeard, Erica L ^a   Sarpa, Nicole M ^a   White, Kenneth E ^a   Econs, Michael J ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; MESSENGER RNA; PHOSPHATE; FIBROBLAST GROWTH FACTOR; N ACETYLGALACTOSAMINYLTRANSFERASE; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOSOMAL DOMINANT HYPOPHOSPHATEMIC RICKETS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE MUTATION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; MALE; MATING; MOUSE; MUTANT; NONHUMAN; PHENOTYPE; PHOSPHATE BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; SKELETON MALFORMATION; TRANSGENE; TUMOR CALCINOSIS; WILD TYPE; AMINO ACID SUBSTITUTION; ANIMAL; C3H MOUSE; C57BL MOUSE; DISEASE MODEL; FAMILIAL HYPOPHOSPHATEMIC RICKETS; GENE THERAPY; GENETICS; GLYCOSYLATION; HYPOPHOSPHATEMIC RICKETS; KNOCKOUT MOUSE; METABOLISM; RICKETS;

AMINO ACID SUBSTITUTION; ANIMALS; DISEASE MODELS, ANIMAL; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FEMALE; FIBROBLAST GROWTH FACTORS; GENETIC THERAPY; GLYCOSYLATION; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; N-ACETYLGALACTOSAMINYLTRANSFERASES; RICKETS; RICKETS, HYPOPHOSPHATEMIC; TRANSGENES;

EID: 84907190432     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1199     Document Type: Article

References (23)

1. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004;19(3):429-435.
2. Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004;145(7):3087-3094.
3. Bai X, Miao D, Li J, Goltzman D, Karaplis AC. Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology. 2004;145(11):5269-5279.
4. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A. 2001;98(11):6500-6505.
5. Shimada T, Yamazaki Y, Takahashi M, et al. Vitamin D receptorindependent FGF23 actions in regulating phosphate and vitamin D metabolism. Am J Physiol Renal Physiol. 2005;289(5):F1088-F1095.
6. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26(3):345-348.
7. White KE, Carn G, Lorenz-Depiereux B, et al. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int. 2001;60(6):2079-2086.
8. Ichikawa S, Baujat G, Seyahi A, et al. Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations. Am J Med Genet A. 2010;152A(4):896-903.
9. Ichikawa S, Lyles KW, Econs MJ. A novel GALNT3 mutation in a pseudoautosomal dominant form of tumoral calcinosis: evidence that the disorder is autosomal recessive. J Clin Endocrinol Metab. 2005;90(4):2420-2423.
10. Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet. 2004;36(6):579-581.
11. Kato K, Jeanneau C, Tarp MA, et al. Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem. 2006; 281(27):18370-18377.
12. Frishberg Y, Ito N, Rinat C, et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 1. J Bone Miner Res. 2007;22(2):235-242
13. Garringer HJ, Mortazavi SMJ, Esteghamat F, et al. Two novel GALNT3mutations in familial tumoral calcinosis.AmJ Med Genet A. 2007;143(20):2390-2396.
14. Ichikawa S, Guigonis V, Imel EA, et al. Novel GALNT3 mutations causing hyperostosis-hyperphosphatemia syndrome result in low intact fibroblast growth factor 23 concentrations. J Clin Endocrinol Metab. 2007;92(5):1943-1947.
15. Ichikawa S, Imel EA, Sorenson AH, et al. Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene. J Clin Endocrinol Metab. 2006;91(11):4472-4475.
16. Ichikawa S, Sorenson AH, Austin AM, et al. Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression. Endocrinology. 2009;150(6):2543-2550.
17. Farrow EG, Yu X, Summers LJ, et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A. 2011;108(46):E1146-E1155.
18. Ichikawa S, Austin AM, Gray AK, Allen MR, Econs MJ. Dietary phosphate restriction normalizes biochemical and skeletal abnormalities in a murine model of tumoral calcinosis. Endocrinology. 2011;152(12):4504-4513.
19. Ichikawa S, Austin AM, Gray AK, Econs MJ. A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells. J Bone Miner Res. 2012;27(2):453-460.
20. Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002;143(8):3179-3182.
21. Imel EA, Peacock M, Gray AK, Padgett LR, Hui SL, Econs MJ. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab. 2011;96(11):3541-3549.
22. Imel EA, Hui SL, Econs MJ. FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res. 2007;22(4):520-526.
23. Myakala K, Motta S, Murer H, et al. Renal-specific and inducible depletion of NaPi-IIc/Slc34a3, the cotransporter mutated inHHRH, does not affect phosphate or calcium homeostasis in mice. Am J Physiol Renal Physiol. 2014;306(8):F833-F843.